Volume 31, Number 6—June 2025
Research
Prospective Multicenter Surveillance of Non–H. pylori Helicobacter Infections during Medical Checkups, Japan
Kengo Tokunaga1
, Emiko Rimbara1 , Toshihisa Tsukadaira, Katsuhiro Mabe, Koji Yahara, Hidekazu Suzuki, Tadashi Shimoyama, Mitsushige Sugimoto, Tadayoshi Okimoto, Hidenori Matsui, Masato Suzuki, Keigo Shibayama, Hiroyoshi Ota, Kazunari Murakami, and Mototsugu Kato
, Emiko Rimbara1 , Toshihisa Tsukadaira, Katsuhiro Mabe, Koji Yahara, Hidekazu Suzuki, Tadashi Shimoyama, Mitsushige Sugimoto, Tadayoshi Okimoto, Hidenori Matsui, Masato Suzuki, Keigo Shibayama, Hiroyoshi Ota, Kazunari Murakami, and Mototsugu Kato
Table 1
Characteristics of patients in study of non–H. pylori Helicobacter infections, Japan, 2022*
| Characteristics | Total, n = 673 | Hospital |
|||
|---|---|---|---|---|---|
| A, n = 100 | B, n = 198 | C, n = 199 | D, n = 176 | ||
| Median age, y (range) |
55 (29–91) |
64 (43–88) |
61 (29–91) |
52 (31–77) |
51 (34–77) |
| Sex | |||||
| M | 390 (57.9) | 47 (47.0) | 119 (60.1) | 111 (55.8) | 113 (64.2) |
| F |
283 (42.1) |
53 (53.0) |
79 (39.9) |
88 (44.2) |
63 (35.8) |
| Endoscopic findings | |||||
| Normal | 322 (47.8) | 56 (56.0) | 114 (57.6) | 73 (36.7) | 79 (44.9) |
| Atrophic gastritis | 340 (50.5) | 41 (41.0) | 80 (40.4) | 125 (62.8) | 94 (53.4) |
| Peptic ulcer | 5 (0.7) | 0 | 2 (1.0) | 0 | 3 (1.7) |
| Gastric cancer | 7 (1.0) | 0 | 1 (0.5) | 0 | 6 (3.4) |
| Nodular gastritis | 20 (3.0) | 1 (1.0) | 1 (0.5) | 8 (4.0) | 10 (5.7) |
| White marble appearance | 80 (11.9) | 0 | 9 (4.5) | 31 (15.6) | 40 (22.7) |
| Crack-like mucosa |
67 (10.0) |
0 |
4 (2.0) |
62 (31.2) |
1 (0.6) |
| Atrophic grading† | |||||
| C-0 | 333 (49.5) | 59 (59.0) | 118 (59.6) | 74 (37.2) | 82 (46.6) |
| C-1 | 133 (19.8) | 5 (5.0) | 14 (7.1) | 90 (45.2) | 24(13.6) |
| C-2 | 116 (17.2) | 15 (15.0) | 30 (15.2) | 35 (17.6) | 36 (20.5) |
| C-3 | 37 (5.5) | 11 (11.0) | 7 (3.5) | 0 | 19 (10.8) |
| O-1 | 22 (3.3) | 6 (6.0) | 9 (4.5) | 0 | 7 (4.0) |
| O-2 | 21 (3.1) | 2 (2.0) | 11 (5.6) | 0 | 8 (4.5) |
| O-3 |
11 (1.6) |
2 (2.0) |
9 (4.5) |
0 |
0 |
| Pets | |||||
| No history | 208 (30.9) | 33 (33.0) | 89 (44.9) | 47 (23.6) | 39 (22.2) |
| Dog | 354 (52.6) | 48 (48.0) | 85 (42.9) | 110 (55.3) | 111 (63.1) |
| Cat |
148 (22.0) |
29 (29.0) |
26 (13.1) |
46 (23.1) |
47 (26.7) |
| Pork offal ingestion | |||||
| No history | 275 (40.9) | 11 (11.0) | 121 (61.1) | 29 (14.6) | 114 (64.8) |
| Sometimes | 347 (51.6) | 78 (78.0) | 75 (37.9) | 154 (77.4) | 40 (22.7) |
| Often |
51 (7.6) |
11 (11.0) |
2 (1.0) |
16 (8.0) |
22 (12.5) |
| Infection status | |||||
| H. pylori infection | 24 (3.6) | 7 (7.0) | 3 (1.5) | 6 (3.0) | 8 (4.5) |
| Posteradication‡ | 256 (38.0) | 35 (35.0) | 72 (36.4) | 61 (30.7) | 88 (50.0) |
| No H. pylori infection | 393 (58.4) | 58 (58.0) | 123 (62.1) | 132 (66.3) | 80 (45.5) |
*Values are no. (%) except as indicated. Hospital A is in Hokkaido, B is in Tokyo, C is in Nagano, and D is in Okayama. †C-0, no atrophy; C-1 and C-2, mild atrophy; C-3 and O-1, moderate atrophy; and O-2 and O-3, severe atrophy. ‡Patients who had previous H. pylori eradication therapy.
1These authors contributed equally to this article.
Page created: March 31, 2025
Page updated: May 27, 2025
Page reviewed: May 27, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.